12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
Ionis Pharmaceuticals Inc (IONS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 2,324,447 | $93,117,347 | -3% | 1.69% |
| 2. | Deep Track Capital David Kroin | 2,200,000 | $88,132,000 | +10% | 2.79% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,920,464 | $76,933,792 | +1009% | 0.09% |
| 4. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,451,879 | $58,162,273 | -55% | 1.7% |
| 5. | 54,500,000 | $56,547,293 | +9% | 2.91% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.23 | 2,500 | Director | 35,219 | 2024-12-23 | Filing | |
| $36.20 | 2,500 | Director | 32,719 | 2024-12-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.70 | 22 | Officer | 184 | 2025-01-16 | Filing | |
| $32.84 | 7,154 | Officer | 45,670 | 2025-01-16 | Filing | |
| $32.79 | 6,523 | Officer | 58,508 | 2025-01-16 | Filing | |
| $32.83 | 7,360 | Officer | 61,203 | 2025-01-16 | Filing | |
| $32.63 | 33,445 | Officer, Director | 207,396 | 2025-01-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,520,872 | $1,088,740,914 | 0.08% | |
| 2. | 14,203,481 | $718,554,104 | 0.01% | |
| 3. | 9,057,530 | $458,220,441 | 0.01% | |
| 4. | 8,713,987 | $440,840,602 | 6.74% | |
| 5. | 4,707,480 | $238,151,403 | 0.2% |
News See All
10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
10 Best Genomics Stocks To Buy Right Now
Genomics is the study of genes and how they function.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2024 Earnings Call Transcript
Operator: Good morning and welcome to the Ionis Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
10 Stocks with Biggest Upside Potential According to Hedge Funds
The US equities saw a strong move after the September jobs report exceeded the economists’ estimates.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Ionis Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript
Operator: Good morning. And welcome to Ionis' First Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.78. Ionis Pharmaceuticals, Inc.
12 Most Promising Gene Editing Stocks According to Hedge Funds
In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds.
Billionaire Hedge Funds
